.png)
DEA Judge Rejects Effort to Reopen Marijuana Rescheduling Hearing: What Happens Next for Cannabis Reform?
November 1, 2026 | Suncoast NORML | Federal Cannabis Policy
The federal government's effort to move marijuana from Schedule I to Schedule III has cleared another procedural hurdle. A Drug Enforcement Administration (DEA) judge has rejected a request from opponents of cannabis reform to reopen hearings and introduce additional testimony. However, the judge will allow limited written arguments concerning a recent federal watchdog report.
The October 22, 2026, decision represents an important development in the ongoing federal marijuana rescheduling process. Although the ruling does not guarantee that cannabis will be moved to Schedule III, it prevents opponents from reopening an extensive evidentiary hearing that has already concluded.
For cannabis patients, businesses, researchers, and legalization advocates in Florida and across the country, the decision raises an important question: Is the federal government finally moving closer to changing marijuana's classification under the Controlled Substances Act?
According to reporting by National NORML, the judge's order establishes a limited briefing schedule while keeping the broader rescheduling proceeding temporarily on hold.
What Did the DEA Judge Decide About Marijuana Rescheduling?
On October 22, DEA Chief Administrative Law Judge Derek C. Julius denied a request to reopen the marijuana rescheduling hearing.
Opponents of the proposed move to Schedule III had requested additional testimony and document discovery following the publication of a Government Accountability Office (GAO) report examining federal drug-scheduling procedures.
Instead, Judge Julius issued a narrower ruling:
The marijuana rescheduling hearing will not reopen for additional testimony or discovery.
The GAO report will be admitted into the official administrative record.
Participating parties may submit additional written briefs addressing the report's relevance.
Initial briefs were due October 29, 2026, with reply briefs due November 5, 2026.
The proceeding remains temporarily stayed until the briefing period concludes.
The judge emphasized that the existing hearing record already contains more than 2,500 pages of witness testimony and thousands of pages of documentary evidence.
Rather than restarting the hearing process, the judge determined that written legal arguments would be sufficient to address the questions raised by the GAO report.
The result: opponents can continue challenging the proposed rescheduling, but they cannot use this particular request to reopen the hearing for another round of evidence gathering.
Why Did Opponents Want to Reopen the Cannabis Hearing?
The request centered on a September 2026 report from the Government Accountability Office examining how the DEA and federal health agencies evaluate controlled substances.
The GAO identified shortcomings in written policies and procedures governing drug-scheduling evaluations.
Opponents argued that these findings warranted additional scrutiny of the federal government's marijuana rescheduling recommendation.
However, Judge Julius determined that the report could be considered without reopening the entire hearing.
The judge limited additional arguments to two central questions:
How much weight should the GAO report receive in the marijuana rescheduling proceeding?
Do the procedural shortcomings identified by the GAO meaningfully affect the validity of the proposed rescheduling decision?
This distinction matters.
The GAO report raises questions about administrative procedures, but those questions do not automatically invalidate the scientific evidence supporting marijuana's recognized medical applications.
The judge's ruling allows the parties to debate the significance of the report without repeating testimony already presented.
Why Is Marijuana Being Considered for Schedule III?
Under the federal Controlled Substances Act, marijuana has historically been classified as a Schedule I substance.
Schedule I is reserved for substances that federal law considers to have a high potential for abuse and no currently accepted medical use in treatment in the United States.
This classification has long been controversial because numerous states, including Florida, have established regulated medical marijuana programs.
In 2023, the U.S. Department of Health and Human Services recommended moving marijuana to Schedule III following a federal scientific and medical review.
The Department of Justice subsequently initiated formal rulemaking to consider the change.
Schedule III substances are recognized under federal law as having accepted medical uses and a lower abuse potential than substances in Schedules I and II.
Moving marijuana to Schedule III would therefore represent a significant shift in federal cannabis policy.
However, rescheduling is not the same as federal marijuana legalization.
Cannabis would remain subject to federal controls, and the change would not automatically authorize recreational marijuana sales nationwide.
What Has Happened With Marijuana Rescheduling in 2026?
The federal marijuana rescheduling process has experienced multiple procedural changes and delays.
The Biden administration initiated the proposed move from Schedule I to Schedule III, but earlier hearing proceedings did not move forward as originally scheduled.
In April 2026, federal officials took action concerning the classification of certain state-authorized medical cannabis products and FDA-approved marijuana products.
Separately, new hearings were ordered to consider the broader proposal to reclassify marijuana products generally.
Those hearings took place during the summer of 2026.
The October 22 ruling concerns that broader proceeding.
It is important to distinguish the limited medical-cannabis action from the ongoing proposal to reschedule marijuana more comprehensively.
The broader federal rescheduling decision remains unresolved.
What Happens Next in the DEA Marijuana Rescheduling Process?
The October 22 order established two important filing deadlines:
October 29, 2026: Deadline for initial briefs concerning the GAO report.
November 5, 2026: Deadline for reply briefs.
After the briefing period closes, the administrative proceeding can advance toward the judge's recommendation.
The administrative law judge's recommendation is not itself the final federal rescheduling decision. Further agency action is required before a comprehensive change in marijuana's classification can take effect.
Although the ruling limits additional evidentiary proceedings, it does not establish a final implementation date for Schedule III.
Advocates and industry stakeholders should therefore distinguish between procedural progress and an actual change in federal law.
What Would Schedule III Mean for Florida Medical Marijuana Patients?
Florida has one of the nation's largest medical marijuana programs, and federal rescheduling could have meaningful implications for the state's cannabis industry and its patients.
1. Greater Federal Recognition of Marijuana's Medical Uses
Moving marijuana to Schedule III would formally recognize that cannabis has accepted medical uses under federal scheduling criteria.
For Florida patients who rely on medical marijuana under state law, that recognition would mark a significant departure from decades of federal prohibition policy.
2. Potential Benefits for Cannabis Research
Schedule I restrictions have historically complicated cannabis research.
Rescheduling could reduce certain regulatory barriers, potentially making it easier to study marijuana's medical applications, safety, and effectiveness.
However, researchers would still need to comply with applicable federal requirements.
3. Major Federal Tax Implications for Cannabis Businesses
One of the most consequential potential effects involves Section 280E of the Internal Revenue Code.
Section 280E generally prevents businesses trafficking in Schedule I or Schedule II controlled substances from deducting many ordinary business expenses.
If marijuana is comprehensively moved to Schedule III, that particular restriction would generally no longer apply to marijuana businesses solely because of marijuana's scheduling status.
For Florida's licensed medical marijuana operators, this could substantially change the federal tax environment.
4. Rescheduling Would Not Automatically Legalize Recreational Marijuana
Florida residents should understand that Schedule III would not, by itself, create a legal adult-use cannabis market.
State laws governing possession, cultivation, licensing, and retail sales would remain important.
Rescheduling also would not automatically establish a federal right for medical marijuana patients to grow cannabis at home.
Those issues require separate legal and policy changes.
Why Suncoast NORML Supports Cannabis Reform Beyond Rescheduling
At Suncoast NORML, we recognize that federal marijuana rescheduling could represent meaningful progress.
But changing marijuana's federal classification is not the finish line.
Decades of cannabis prohibition have contributed to criminal penalties, barriers to scientific research, and consequences for individuals and families.
Moving marijuana to Schedule III would not automatically eliminate those harms.
Comprehensive cannabis reform must also address:
Ending criminal penalties for responsible adult cannabis use.
Protecting medical marijuana patients from discrimination.
Expunging eligible marijuana-related criminal records.
Allowing responsible adults to cultivate cannabis at home.
Establishing fair and equitable cannabis regulations.
Respecting voters' ability to determine marijuana policy through democratic processes.
Rescheduling acknowledges marijuana's medical value. Legalization and broader criminal justice reform address the consequences of prohibition.
Both conversations are essential.
Is Federal Marijuana Rescheduling Finally Moving Forward?
The October 22 decision is a procedural setback for opponents seeking additional testimony, but it is not a final victory for cannabis reform.
The judge has declined to reopen the hearing while allowing the parties to address concerns raised by the GAO report.
That approach keeps the process moving toward its next stage without disregarding the legal questions raised by opponents.
The larger issue remains whether federal marijuana policy will finally reflect the medical evidence, evolving state laws, and changing public attitudes surrounding cannabis.
For millions of Americans living in states with medical or adult-use marijuana programs, the answer has implications far beyond a federal scheduling designation.
Frequently Asked Questions About DEA Marijuana Rescheduling
Has marijuana officially been moved to Schedule III?
The broader proposal to move marijuana to Schedule III has not been finalized through the hearing discussed in this article. The October 22 ruling concerns procedural issues in that ongoing proceeding.
Did the DEA judge approve marijuana rescheduling?
No. Judge Derek Julius denied a request to reopen the hearing and permitted limited additional briefs. He did not issue a final ruling approving the proposed comprehensive rescheduling.
When will marijuana become Schedule III?
There is no confirmed final implementation date for the broader rescheduling proposal. The next briefing deadline identified in the October 22 order is November 5, 2026.
Will Schedule III make recreational marijuana legal in Florida?
No. Federal rescheduling would not automatically legalize recreational marijuana in Florida or establish a nationwide adult-use cannabis market.
Will marijuana rescheduling allow Florida patients to grow cannabis at home?
No. Moving marijuana to Schedule III would not automatically authorize home cultivation. Florida's medical marijuana laws would still govern patient access and cultivation restrictions.
What is the difference between marijuana rescheduling and descheduling?
Rescheduling moves marijuana from one controlled-substance category to another. Descheduling removes marijuana from the federal controlled-substance schedules altogether. Descheduling would be a more fundamental change to federal marijuana prohibition.
Why is the Government Accountability Office involved?
The GAO published a report examining federal drug-scheduling policies and procedures. Opponents of marijuana rescheduling argued that the report raised questions about the government's evaluation process. The judge admitted the report into the record but declined to reopen the hearing.
The Bottom Line: Cannabis Reform Must Go Beyond Schedule III
The DEA judge's decision to reject another round of testimony represents meaningful procedural progress in the federal marijuana rescheduling process.
But marijuana rescheduling remains unfinished, and even a successful move to Schedule III would leave significant elements of federal prohibition intact.
Suncoast NORML will continue advocating for policies grounded in scientific evidence, individual liberty, patient protections, and sensible cannabis regulation.
Florida patients and voters deserve more than incremental changes to federal drug classifications. They deserve cannabis laws that prioritize public health, personal freedom, and justice.
Stay informed about federal and Florida cannabis policy developments by following Suncoast NORML and watching The Rotation, our weekly podcast discussing marijuana reform, politics, and the latest cannabis news.
Sources and Further Reading
Primary Source: National Organization for the Reform of Marijuana Laws (NORML), October 22, 2026.
Additional official resource: DEA Proposed Marijuana Rescheduling Proceedings and Orders
This article was prepared by Suncoast NORML using reporting originally published by National NORML. We acknowledge and thank National NORML for its continued coverage of federal marijuana policy and cannabis reform.
Comments